Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Jun;22(6 Suppl):II15-20.
doi: 10.1002/clc.4960221404.

Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects

Affiliations
Review

Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects

H N Hodis et al. Clin Cardiol. 1999 Jun.

Abstract

Invasive and noninvasive arterial imaging are important techniques used to study atherosclerosis and, specifically, to evaluate the atherogenecity of triglyceride-rich lipoproteins (TRL). Serial coronary angiography trials show significant benefit from lowering low-density lipoprotein cholesterol (LDL-C) which serves to retard lesion progression. Even with aggressive LDL-C reduction, however, up to half of patients demonstrate continued progression of atherosclerosis. Angiographic studies reveal that lowering LDL-C has the most impact on severe lesions, those > or = 50% diameter stenosis, whereas TRL (and their apolipoprotein markers) have been identified as a driving factor behind progression of mild-to-moderate lesions < 50% diameter stenosis. Quantitative coronary angiography (QCA) has demonstrated that progression of mild-to-moderate lesions are among the most significant predictors of clinical coronary events, and that lowering TRL reduces progression of coronary artery disease to the same degree as the lowering of LDL-C.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Blankenhorn DH, Hodis HN: Duff Memorial Lecture: Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14: 177–192 - PubMed
    1. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH: Triglyceride and cholesterol‐rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42–49 - PubMed
    1. Mack WJ, Krauss RM, Hodis HN: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16: 697–704 - PubMed
    1. Alaupovic P, Mack WJ, Knight‐Gibson C, Hodis HN: The role of triglyceride‐rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997; 17: 715–722 - PubMed
    1. Hodis HN, Mack WJ, Dunn M, Liu CR, Liu CH, Selzer RH, Krauss RM: Intermediate‐density lipoproteins and progression of carotid arterial wall intima‐media thickness. Circulation 1997; 95: 2022–2026 - PubMed

MeSH terms